Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mauricio Tohen

Showing results (61-70 of 260) with videos related to

Pageof 26
Sort By:
Journal of Affective Disorders|January 1, 2003
Placebo-controlled trials do not find association of olanzapine with exacerbation of bipolar maniaRobert W Baker, Denái R Milton, Virginia L Stauffer, et al.
Harvard Review of Psychiatry|April 27, 2010
Bipolar depression: overview and commentaryRoss J Baldessarini, Eduard Vieta, Joseph R Calabrese, et al.
The Journal of Clinical Psychiatry|November 13, 2009
Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysisFranco Benazzi, Michael Berk, Mark A Frye, et al.
International Journal of Bipolar Disorders|October 28, 2024
Aripiprazole once-monthly for the treatment of adult patients with earlier-stage bipolar I disorder: a post hoc analysis of data from a double-blind, placebo-controlled, 52-week randomized withdrawal trialKarimah S Bell Lynum, Christine F Castro, Zhen Zhang, et al.
Journal of Affective Disorders|March 28, 2006
Clinical relevance of depressive symptom improvement in bipolar I depressed patientsDoug Williamson, Eileen Brown, Roy H Perlis, et al.
Journal of Affective Disorders|December 8, 2021
Chronbiologically-based sub-groups in bipolar I disorder: A latent profile analysisRobert Gonzalez, Alok Dwivedi, Jamie Zeitzer, et al.
The Primary Care Companion for CNS Disorders|June 8, 2017
Patient Characteristics Associated With Use of Lurasidone Versus Other Atypical Antipsychotics in Patients With Bipolar Disorder: Analysis From a Claims Database in the United StatesMauricio Tohen, Daisy Ng-Mak, Krithika Rajagopalan, et al.
The Journal of Clinical Psychiatry|February 5, 2009
Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic studyHaya Ascher-Svanum, Baojin Zhu, Douglas Faries, et al.
International Clinical Psychopharmacology|July 15, 2025
Long-term safety and tolerability of lumateperone 42 mg in patients with bipolar disorder: results from a 6-month open-label extension studyMauricio Tohen, Suresh Durgam, Susan G Kozauer, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|April 15, 2023
Antidepressant efficacy of cariprazine in bipolar disorder and the role of its pharmacodynamic properties: A hypothesis based on dataKonstantinos N Fountoulakis, Magdalini Ioannou, Mauricio Tohen, et al.
Pageof 26

Showing results (61-70 of 260) with videos related to

Sort By:
Pageof 26
Journal of Affective Disorders|January 1, 2003
Placebo-controlled trials do not find association of olanzapine with exacerbation of bipolar maniaRobert W Baker, Denái R Milton, Virginia L Stauffer, et al.
Harvard Review of Psychiatry|April 27, 2010
Bipolar depression: overview and commentaryRoss J Baldessarini, Eduard Vieta, Joseph R Calabrese, et al.
The Journal of Clinical Psychiatry|November 13, 2009
Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysisFranco Benazzi, Michael Berk, Mark A Frye, et al.
International Journal of Bipolar Disorders|October 28, 2024
Aripiprazole once-monthly for the treatment of adult patients with earlier-stage bipolar I disorder: a post hoc analysis of data from a double-blind, placebo-controlled, 52-week randomized withdrawal trialKarimah S Bell Lynum, Christine F Castro, Zhen Zhang, et al.
Journal of Affective Disorders|March 28, 2006
Clinical relevance of depressive symptom improvement in bipolar I depressed patientsDoug Williamson, Eileen Brown, Roy H Perlis, et al.
Journal of Affective Disorders|December 8, 2021
Chronbiologically-based sub-groups in bipolar I disorder: A latent profile analysisRobert Gonzalez, Alok Dwivedi, Jamie Zeitzer, et al.
The Primary Care Companion for CNS Disorders|June 8, 2017
Patient Characteristics Associated With Use of Lurasidone Versus Other Atypical Antipsychotics in Patients With Bipolar Disorder: Analysis From a Claims Database in the United StatesMauricio Tohen, Daisy Ng-Mak, Krithika Rajagopalan, et al.
The Journal of Clinical Psychiatry|February 5, 2009
Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic studyHaya Ascher-Svanum, Baojin Zhu, Douglas Faries, et al.
International Clinical Psychopharmacology|July 15, 2025
Long-term safety and tolerability of lumateperone 42 mg in patients with bipolar disorder: results from a 6-month open-label extension studyMauricio Tohen, Suresh Durgam, Susan G Kozauer, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|April 15, 2023
Antidepressant efficacy of cariprazine in bipolar disorder and the role of its pharmacodynamic properties: A hypothesis based on dataKonstantinos N Fountoulakis, Magdalini Ioannou, Mauricio Tohen, et al.
Pageof 26